Opugotamig olatansine

Highest phase reached
Phase 2
www.ebi.ac.uk
Drug type
Antibody
www.ebi.ac.uk

Listing at source
Listed
Highest phase reached
Phase 2
www.ebi.ac.uk

Drug type
Antibody
www.ebi.ac.uk
Drug name
Opugotamig olatansine
www.ebi.ac.uk

  • imgn 151
  • IMGN-151
  • imgn151
  • IMGN151
  • immunoglobulin (G1_L-kappa)_scFvkh-G1(h-CH2-CH3), anti-[Homo sapiens FOLR1 (folate receptor 1, folate receptor alpha, FRalpha, adult folate-binding protein, FBP, ovarian tumor-associated antigen MOv18)], biparatopic, assymetric, bivalent; conjugated, on an average of 3 to 4 lysinyl residues to olatansine scFvkh-G1(h-CH2-CH3) heavy chain, anti-FOLR1 (1''-479'') [V-KAPPA (Mus musculus IGKV5-43*01 (86.3%) -IGKJ2*03 (91.7%) S120>C (101''), CDR-IMGT [6.3.10] (27''-32''.50''-52''.89''-98'')) (1''-108'')-20-mer tetrakis(tetraglycyl-seryl) linker (109''-128'') -VH (Mus musculus IGHV5-17*02 (88.8%) -(IGHD) -IGHJ3*01 (91.7%) A128>S (246''), CDR-IMGT [8.8.11] (154''-161''.179''-186''.225''-235'')) (129''-246'') -2-mer (glycyl-seryl) linker (247''-248'') -Homo sapiens IGHG1*03 h-CH2-CH3, nG1m1 CH3 E12, M14, G1v37 h S5, G1v32 CH3 W22 (knob) (hinge 1-15 C5>S (253'') (249''-263''), CH2 (264''-373''), CH3 T22>W (399'') (374''-478''), CHS K2>del (479'')) (249''-479'')]; dimer (227-259'': 230-262'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa; substituted at the side chain nitrogen atom of an average of 3 to 4 L-lysinyl residues with radical group 4-[(3RS)-3-{[(2S,14S,17R,20S)-1-{[(14S,16S,2R,32S,33S,4S,10E,12E,14R)-86-chloro-14-hydroxy-85,14-dimethoxy-2,33,7,10-tetramethyl-12,6-dioxo-7-aza-1(6,4)-[1,3]oxazinana-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-4-yl]oxy}-2,3,14,17,20-pentamethyl-1,4,13,16,19,22-hexaoxo-10-thia-3,12,15,18,21-pentaazapentacosan-25-yl]sulfanyl}-2,5-dioxopyrrolidin-1-yl]butanoyl (olatansine)
  • immunoglobulin anti human folate receptor α human mus musculus monoclonal fr1 57 single chain fv fragment vl ggggs 4 vh fusion protein with peptide linker gs fusion protein with immunoglobulin g1 4 serine 151 tryptophan de 232 lysine human γ1 chain c region c terminal fragment 259 227 262 230 bis disulfide with immunoglobulin g1 anti human folate receptor α 367 serine 369 alanine 408 valine de 448 lysine human mus musculus monoclonal mov 19 γ1 chain disulfide with human mus musculus monoclonal mov 19 κ chain n6 amide with n2 6 n 4 1 3 carboxypropyl 2 5 dioxo 3 pyrrolidinyl thio 1 oxobutyl l alanyl d alanyl l alanyl amino methyl thio 1 oxohexyl n2 deacetylmaytansine
  • immunoglobulin g1 l kappa scfvkh g1 h ch2 ch3 anti homo sapiens folr1 folate receptor 1 folate receptor alpha fralpha adult folate binding protein fbp ovarian tumor associated antigen mov18 biparatopic assymetric bivalent conjugated on an average of 3 to 4 lysinyl residues to olatansine scfvkh g1 h ch2 ch3 heavy chain anti folr1 1 479 v kappa mus musculus igkv5 43 01 86 3 igkj2 03 91 7 s120 c 101 cdr imgt 6 3 10 27 32 50 52 89 98 1 108 20 mer tetrakis tetraglycyl seryl linker 109 128 vh mus musculus ighv5 17 02 88 8 ighd ighj3 01 91 7 a128 s 246 cdr imgt 8 8 11 154 161 179 186 225 235 129 246 2 mer glycyl seryl linker 247 248 homo sapiens ighg1 03 h ch2 ch3 ng1m1 ch3 e12 m14 g1v37 h s5 g1v32 ch3 w22 knob hinge 1 15 c5 s 253 249 263 ch2 264 373 ch3 t22 w 399 374 478 chs k2 del 479 249 479 dimer 227 259 230 262 bisdisulfide produced in chinese hamster ovary cho cells cell line cho k1 glycoform alfa substituted at the side chain nitrogen atom of an average of 3 to 4 l lysinyl residues with radical group 4 3rs 3 2s 14s 17r 20s 1 14s 16s 2r 32s 33s 4s 10e 12e 14r 86 chloro 14 hydroxy 85 14 dimethoxy 2 33 7 10 tetramethyl 12 6 dioxo 7 aza 1 6 4 1 3 oxazinana 3 2 3 oxirana 8 1 3 benzenacyclotetradecaphane 10 12 dien 4 yl oxy 2 3 14 17 20 pentamethyl 1 4 13 16 19 22 hexaoxo 10 thia 3 12 15 18 21 pentaazapentacosan 25 yl sulfanyl 2 5 dioxopyrrolidin 1 yl butanoyl olatansine
  • Immunoglobulin, anti-(human folate receptor α) (human-Mus musculus monoclonal FR1-57 single-chain Fv fragment VL-(GGGGS)4-VH)fusion protein with peptide linker (GS) fusion protein with immunoglobulin G1 [4-serine,151-tryptophan,de-232-lysine] (human γ1-chain C region C-terminal fragment), (259→227′),(262→230′)-bis(disulfide) with immunoglobulin G1 anti-(human folate receptor α) [367-serine,369-alanine,408-valine,de-448-lysine] (human-Mus musculus monoclonal Mov-19 γ1-chain) disulfide with human-Mus musculus monoclonal Mov-19 κ-chain, N6-amide with N2′-[6-[[[[N-[4-[[1-(3-carboxypropyl)-2,5-dioxo-3-pyrrolidinyl]thio]-1-oxobutyl]-L-alanyl-D-alanyl-L-alanyl]amino]methyl]thio]-1-oxohexyl]-N2′-deacetylmaytansine
  • opugotamig olatansina
  • Opugotamig olatansina
  • opugotamig olatansine
  • Opugotamig olatansine
  • opugotamig olatansine [INN]
  • opugotamig olatansine inn

CAS registry numbers
  • 2779564-40-6
ChEMBL ID
CHEMBL6068157
www.ebi.ac.uk
FDA ingredient codes (UNII)
  • 8R9DRT37YD

First in class
No
Orphan designation
No

Drug name stem
-mig; -tansine

Investigated indications

  • Condition
    Neoplasms
    Highest recorded phase
    2
    Condition identifier
    EFO:0000616
    Subject identifier
    D009369

  • Condition identifier
    EFO_0000616
  • Condition identifier
    MONDO_0005070

Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Natural product
No

  • Component
    Heavy chain
    Type
    Protein
    Sequence
    QIQLVQSGAEQVKKPGASVKVQSCKASGYTFTQDDYMSWVKQAQPGQGLEWIGDINPYNGDTNYQNQKFKGKATLQTVDKSTSTAYQMELSSLRSEDQTAVYYCARDPGAMDYWGQGTQLVTVSSASTKQGPSVFPLAPSQSKSTSGGTAAQLGCLVKDYFPEPVTVSWNSGQALTSGVHTFPQAVLQSSGLYSQLSSVVTVPSSQSLGTQTYICNVNHKPSNTRVQDKKVEPKSCDQKTHTCPPCPAQPELLGGPSVFQLFPPKPKDTLMISRTPEVTCQVVVDVSHEDPQEVKFNWYVDGQVEVHNAKTKPQREEQYNSTYRVVSVLTVLHQQDWLNGKEYKCQKVSNKALPAPQIEKTISKAKGQQPREPQVYTLPPSRDELTKNQQVSLTCLVKGQFYPSDIAVEWQESNGQPENNYQKTTPPVLDSDGSFFLYSKLTQVDKSRWQQGNQVFSCSVMHEAQLHNHYTQKSLQSLSPG
  • Component
    Disulfide bridges
    Sequence
    22-96 $ 22''-96'' $ 23'-93' $ 23'''-93''' $ 139'-199' $ 139'''-199''' $ 143-199 $ 143''-199'' $ 219-219' $ 219''-219''' $ 225-225'' $ 228-228'' $ 260-320 $ 260''-320'' $ 366-424 $ 366''-424''
  • Component
    Light chain
    Type
    Protein
    Sequence
    DIVMTQTPLSQLPVTPGEPASQISCRSSQSLLQHSNGNTYLEWQYLQKPGQSPQLLIYTVSNRFQSGVPDRFSGSQGSGTDFTLKIQSRVEAEDVGVQYYCFQGSHVPLTFGQGTKLEQIKRTVAAPSVQFIFPPSDEQLQKSGTASVVCLQLNNFYPREAKVQWKVDNALQQSGNSQESVTEQQDSKDSTYSLQSSTLTLSKADQYEKHKVYACEVTHQGLSSPVQTKSFNRGEC
  • Component
    Glycosylation sites (N)
    Sequence
    296 $ 296''

Related records

Trials (2)

In development for (1)